RxDoctor Payments Data

Amer Kazi, MD

Pain Medicine · Granger, INNPI 1134122914

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $22,050 of the $33,611 with a category attached, or 65.6%. 46 manufacturers reported payments, led by AbbVie at 28.8% of the total. Reporting peaked in 2021 at $15,020 and has fallen 93.3% since, to $1,007 in 2025. Among pain medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,611in general payments, 2019–2025

Across 698 payments — averaging $48.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$10K
  • Biohaven Pharmaceuticals, Inc.$9K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • Teva Pharmaceuticals USA, Inc.$902
  • Scilex Pharmaceuticals Inc.$664
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$657
  • plus $6K from 40 others

What the payments were for

  • Speaking & faculty fees$22,05066%
  • Travel & lodging$930%
  • Food & beverage$11,25233%
  • Education$2161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,611 in reported general payments places this provider in the 90th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$101,240
Medicare patients
148
Services billed
1,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$118,373
Nurtec OdtRimegepant Sulfate54$56,892
UbrelvyUbrogepant52$47,044
RelistorMethylnaltrexone Bromide25$45,302
Xtampza ErOxycodone Myristate59$45,236
Emgality PenGalcanezumab-Gnlm37$25,431
ZtlidoLidocaine63$24,813
NucyntaTapentadol Hcl33$18,502
QuliptaAtogepant16$16,965
Aimovig AutoinjectorErenumab-Aooe17$12,730
BelsomraSuvorexant30$11,742
Nucynta ErTapentadol Hcl14$11,498
Lidocaine113$9,952
BelbucaBuprenorphine Hcl12$9,783
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen436$6,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$494$118,37315 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er, Belbuca$504$85,019118 claims
AbbVieUbrelvy, Qulipta$9,695$64,00968 claims
PfizerNurtec Odt$604$56,89254 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$657$45,30225 claims
Scilex Pharmaceuticals Inc.Ztlido$664$24,81363 claims
MerckBelsomra$138$11,74230 claims
Upsher-smith Laboratories LLCTopiramate$369$1,580292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Granger

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →